BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 36500249)

  • 1. The Dietary Flavonol Kaempferol Inhibits Epstein-Barr Virus Reactivation in Nasopharyngeal Carcinoma Cells.
    Wu CC; Lee TY; Cheng YJ; Cho DY; Chen JY
    Molecules; 2022 Nov; 27(23):. PubMed ID: 36500249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of Epstein-Barr virus reactivation in nasopharyngeal carcinoma cells by dietary sulforaphane.
    Wu CC; Chuang HY; Lin CY; Chen YJ; Tsai WH; Fang CY; Huang SY; Chuang FY; Lin SF; Chang Y; Chen JY
    Mol Carcinog; 2013 Dec; 52(12):946-58. PubMed ID: 22641235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Luteolin inhibits Epstein-Barr virus lytic reactivation by repressing the promoter activities of immediate-early genes.
    Wu CC; Fang CY; Hsu HY; Chen YJ; Chou SP; Huang SY; Cheng YJ; Lin SF; Chang Y; Tsai CH; Chen JY
    Antiviral Res; 2016 Aug; 132():99-110. PubMed ID: 27185626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EBV reactivation as a target of luteolin to repress NPC tumorigenesis.
    Wu CC; Fang CY; Hsu HY; Chuang HY; Cheng YJ; Chen YJ; Chou SP; Huang SY; Lin SF; Chang Y; Tsai CH; Chen JY
    Oncotarget; 2016 Apr; 7(14):18999-9017. PubMed ID: 26967558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural Variations in BRLF1 Promoter Contribute to the Elevated Reactivation Level of Epstein-Barr Virus in Endemic Areas of Nasopharyngeal Carcinoma.
    Zhang JB; Huang SY; Wang TM; Dong SQ; He YQ; Zheng XH; Li XZ; Wang F; Jianbing M; Jia WH
    EBioMedicine; 2018 Nov; 37():101-109. PubMed ID: 30420297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Epstein-Barr virus reactivation by the flavonoid apigenin.
    Wu CC; Fang CY; Cheng YJ; Hsu HY; Chou SP; Huang SY; Tsai CH; Chen JY
    J Biomed Sci; 2017 Jan; 24(1):2. PubMed ID: 28056971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interplay between PKCδ and Sp1 on histone deacetylase inhibitor-mediated Epstein-Barr virus reactivation.
    Tsai PF; Lin SJ; Weng PL; Tsai SC; Lin JH; Chou YC; Tsai CH
    J Virol; 2011 Mar; 85(5):2373-85. PubMed ID: 21159880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emodin Inhibits EBV Reactivation and Represses NPC Tumorigenesis.
    Wu CC; Chen MS; Cheng YJ; Ko YC; Lin SF; Chiu IM; Chen JY
    Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31731581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of ARKL1 as a Negative Regulator of Epstein-Barr Virus Reactivation.
    Siddiqi UZ; Vaidya AS; Li X; Marcon E; Tsao SW; Greenblatt J; Frappier L
    J Virol; 2019 Oct; 93(20):. PubMed ID: 31341047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epstein-Barr Virus BRLF1 Induces PD-L1 Expression in Nasopharyngeal Carcinoma Cells.
    Wu CC; Chen MS; Lee TY; Huang TS; Cho DY; Chen JY
    Viral Immunol; 2024 Mar; 37(2):115-123. PubMed ID: 38498796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epstein-Barr virus mRNA profiles and viral DNA methylation status in nasopharyngeal brushings from nasopharyngeal carcinoma patients reflect tumor origin.
    Ramayanti O; Juwana H; Verkuijlen SA; Adham M; Pegtel MD; Greijer AE; Middeldorp JM
    Int J Cancer; 2017 Jan; 140(1):149-162. PubMed ID: 27600027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Epstein-Barr virus oncoprotein LMP1-mediated high oxidative stress suppresses EBV lytic reactivation and sensitizes tumors to radiation therapy.
    Hu J; Li Y; Li H; Shi F; Xie L; Zhao L; Tang M; Luo X; Jia W; Fan J; Zhou J; Gao Q; Qiu S; Wu W; Zhang X; Liao W; Bode AM; Cao Y
    Theranostics; 2020; 10(26):11921-11937. PubMed ID: 33204320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baicalein inhibits growth of Epstein-Barr virus-positive nasopharyngeal carcinoma by repressing the activity of EBNA1 Q-promoter.
    Zhang Y; Wang H; Liu Y; Wang C; Wang J; Long C; Guo W; Sun X
    Biomed Pharmacother; 2018 Jun; 102():1003-1014. PubMed ID: 29710517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytolytic virus activation therapy and treatment monitoring for Epstein-Barr virus associated nasopharyngeal carcinoma in a mouse tumor model.
    Novalić Z; Verkuijlen SAWM; Verlaan M; Eersels JLH; de Greeuw I; Molthoff CFM; Middeldorp JM; Greijer AE
    J Med Virol; 2017 Dec; 89(12):2207-2216. PubMed ID: 28853217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An epidemiological and molecular study of the relationship between smoking, risk of nasopharyngeal carcinoma, and Epstein-Barr virus activation.
    Xu FH; Xiong D; Xu YF; Cao SM; Xue WQ; Qin HD; Liu WS; Cao JY; Zhang Y; Feng QS; Chen LZ; Li MZ; Liu ZW; Liu Q; Hong MH; Shugart YY; Zeng YX; Zeng MS; Jia WH
    J Natl Cancer Inst; 2012 Sep; 104(18):1396-410. PubMed ID: 22972969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of lytic cycle of Epstein-Barr virus by suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinoma.
    Hui KF; Ho DN; Tsang CM; Middeldorp JM; Tsao GS; Chiang AK
    Int J Cancer; 2012 Oct; 131(8):1930-40. PubMed ID: 22261816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epstein-Barr virus-driven metabolic alterations contribute to the viral lytic reactivation and tumor progression in nasopharyngeal carcinoma.
    Shi F; Shang L; Zhou M; Lv C; Li Y; Luo C; Liu N; Lu J; Tang M; Luo X; Xu J; Fan J; Zhou J; Gao Q; Wu W; Jia W; Wang H; Cao Y
    J Med Virol; 2024 May; 96(5):e29634. PubMed ID: 38682578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of methylation status of Epstein-Barr virus DNA C promoter in the diagnosis of nasopharyngeal carcinoma.
    Zheng XH; Wang RZ; Li XZ; Zhou T; Zhang JB; Zhang PF; Lu LX; Jia WH
    Cancer Sci; 2020 Feb; 111(2):592-600. PubMed ID: 31834989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of Epstein-Barr virus lytic gene BRLF1 in nasopharyngeal carcinoma: potential use in diagnosis.
    Feng P; Ren EC; Liu D; Chan SH; Hu H
    J Gen Virol; 2000 Oct; 81(Pt 10):2417-2423. PubMed ID: 10993929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cancer-associated Epstein-Barr virus BZLF1 promoter variant enhances lytic infection.
    Bristol JA; Djavadian R; Albright ER; Coleman CB; Ohashi M; Hayes M; Romero-Masters JC; Barlow EA; Farrell PJ; Rochford R; Kalejta RF; Johannsen EC; Kenney SC
    PLoS Pathog; 2018 Jul; 14(7):e1007179. PubMed ID: 30052684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.